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Abstract
Aims
Dilated cardiomyopathy (DCM) is an important cause of heart failure with a strong familial
component. We performed an exome-wide array-based association study (EWAS) to
assess the contribution of missense variants to sporadic DCM.
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Methods and results
116,855 single nucleotide variants (SNVs) were analyzed in 2796 DCM patients and 6877
control subjects from 6 populations of European ancestry. We confirmed two previously
identified associations with SNVs in BAG3 and ZBTB17 and discovered six novel DCM-
associated loci (Q-value<0.01). The lead-SNVs at novel loci are common and located in
TTN, SLC39A8, MLIP, FLNC, ALPK3 and FHOD3. In silico fine mapping identified HSPB7
as the most likely candidate at the ZBTB17 locus. Rare variant analysis (MAF<0.01) demon-
strated significant association for TTN variants only (P = 0.0085). All candidate genes but
one (SLC39A8) exhibit preferential expression in striated muscle tissues and mutations in
TTN, BAG3, FLNC and FHOD3 are known to cause familial cardiomyopathy. We also inves-
tigated a panel of 48 known cardiomyopathy genes. Collectively, rare (n = 228, P = 0.0033)
or common (n = 36, P = 0.019) variants with elevated in silico severity scores were associ-
ated with DCM, indicating that the spectrum of genes contributing to sporadic DCM extends
beyond those identified here.
Conclusion
We identified eight loci independently associated with sporadic DCM. The functions of the
best candidate genes at these loci suggest that proteostasis regulation might play a role in
DCM pathophysiology.
Introduction
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by left ventricular dila-
tation and systolic dysfunction in the absence of abnormal loading conditions or coronary
artery disease (CAD). DCM is a major cause of sudden cardiac death and heart failure often
requiring heart transplantation, its population-frequency is estimated to be around 1/500 [1].
Genetic studies of familial DCM have identified rare causal variants in more than 50 genes [2].
Genome-Wide Association Studies (GWAS) of sporadic DCM have revealed a few common
variants associated with the disease [3]. A locus on chromosome 1 encompassing ZBTB17,
HSPB7 and CLCNKA, was replicated in several studies [3,4]. However, attempts to correlate
the functions of these genes to DCM remained inconclusive[5]. In our prior GWAS, we also
identified an association with a missense variant in BAG3 and demonstrated the implication of
BAG3 mutations in familial DCM [3].
Our prior GWAS had a limited sample size and used a genome-wide tagging array to esti-
mate allele frequencies in stratified pools of DNA. We now report the results of an extended
study in 6 populations of European ancestry, using the Illumina Human Exome Beadchip
which mostly targets variants altering protein sequence (http://genome.sph.umich.edu/wiki/
Exome_Chip_Design). We report association analyses for single variants, candidate regions
and a panel of 48 genes implicated in familial cardiomyopathy [2].To maximize power and
because DCM is a relatively rare disease we conducted exome-wide genotyping in all available
patients and controls instead of using a two-step discovery/replication design.
Methods
See S1Methods for details, in brief:
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Ethics statement
Written informed consent was obtained from all study participants. All samples were collected
in accordance with the Helsinki declaration and study protocols were approved by the ethics
committees of the participating centers: UK population: Southampton and south west Hamp-
shire research ethics committee (09/H0504/104); USA population 1: The Partners Human
Research Committee, IRB of Partners Healthcare, Brigham and Women’s Hospital; USA pop-
ulation 2: MAGNet study—University of Pennsylvania Institutional Review Board; Eurogene
Ethics: CPP comite´ de protection des personnes dans la recherche biome´dicale, Faculty hospi-
tal Pitie´-Salpêtrière, Paris (ref 66–01); Cardigene Ethics: CPP comite´ de protection des per-
sonnes dans la recherche biome´dicale, Faculty hospital Pitie´-Salpêtrière, Paris; PHRC Ethics:
CPP comite´ de protection des personnes dans la recherche biome´dicale, Faculty hospital Pitie´-
Salpêtrière, Paris (ref 63–05); German population- Charite University Hospital Ethics Com-
mittee, Berlin, Germany.
Populations included and samples collection
All subject included in the study gave informed consent; the research protocol was approved by
local ethic committees and complies with the Declaration of Helsinki. Patients with sporadic idi-
opathic DCM and controls from six populations of European descent, recruited in Germany,
France, UK, USA and Italy, were included in this EWAS. Sporadic DCM was diagnosed accord-
ing to standard criteria and known secondary causes of the disease as well as familial cases (when
relevant information was available) were excluded. Control subjects from the same country of
origin were selected for each group of patients except for the MAGNet Study patients (USA2
population) for whom a control group was artificially defined by subsampling 1,000 individuals
from the German control group (see S1Methods—Variant-level analysis).
Genotyping and data preprocessing
Genotyping was done with Illumina HumanExome BeadChips using a standard protocol. Qual-
ity control was performed with the 1.9 version of the PLINK software [6] and in the R version
3.1 environment. Markers with genotyping success rate<99% and samples with<99% of
markers available were excluded.
Protein interaction study
HEK293 cells were transfected with vectors encoding for GFP-tagged BAG3 or GFP (as a nega-
tive control). 48h post-transfection cell lysates were subjected to 2 independent protein inter-
action analyses. For GST pull-down experiments, HEK293 cells were transfected with vectors
expressing GFP alone or GFP-tagged BAG3 proteins. Total cell lysates were incubated with
Glutathione Sepharose beads complexed with GST-HspB7 recombinant proteins. GST tagged
HspB7 proteins were purified from a bacterial expression system (BL21 E. coli). For co-immu-
noprecipitation, HEK293 cells were co-transfected with Flag-HSPB7 and GFP or GFP-BAG3
vectors. Total cell lysates were incubated with magnetic Protein A Dynabeads and subjected to
immunoprecipitation using an anti-GFP antibody. Input fractions, GST-pull down and GFP-
coimmunoprecipitated proteins, were revealed by Western-Blot.
Statistical analysis
All statistical models were adjusted on age and gender and on the 20 first principal compo-
nents (PCs) estimated from the genetic relatedness matrix (GRM) [7] to account for a possible
population stratification.
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Variant-level analysis
Association between case-control status and each variant was assessed using logistic regres-
sion, variant effect being modeled either as additive or dominant in PLINK. Homogeneity of
effects of DCM-associated variants across populations was tested by a meta-analysis of popula-
tion-specific data. To account for false discovery rate, a Q-value (R/Qvalue package) threshold
of 0.01 was chosen. S1A Table reports the power of our study for various MAF and allelic risk.
Region and gene set-level analyses
We used SKAT [8] to evaluate the global contribution of sets of variants. The analysis was per-
formed for rare (MAF<0.01), common, and all variants combined. Regional analyses were
centered on the candidate regions discovered in the variant-level analyses. For the gene-set
analysis, genes known to be implicated in familial cardiomyopathy were identified [2] and all
available variants on these genes were tested both at the gene level and as a whole. S1B Table
reports the power of our study for the gene set analyzes.
Fine mapping by imputing variants in the regions of interest
To identify non-genotyped variants in strong linkage disequilibrium (LD) with the lead-SNVs,
imputation was performed across regions encompassing the loci identified in the variant-level
analysis [9].
Bioinformatics resources
Variant functionality was assessed using the Combined Annotation Dependent Depletion
(CADD) framework [10]. We also determined tissue-specific gene expression in silico using
the Genotype-Tissue Expression (GTEx) database [11].
Results
The study included 2796 DCM patients (643 females) and 6877 control subjects (3045 females)
(S2 Table). After exclusion of variants that were monomorphic in cases and controls, 95499
SNVs were available for analysis. At 1% Q-value, 11 SNVs at 8 distinct loci are significantly
associated to DCM (Fig 1, Table 1). Re-analysis of the data after removal of the 85 cases with
identified familial DCM forms did not modify the results (S7 Table). Two of these loci were
previously identified (ZBTB17-HSPB7 and BAG3) and six are novel (TTN, SLC39A8, MLIP,
FLNC, NMB-ALPK3, FHOD3). The QQ-plot of association statistics (S1 Fig) shows that popu-
lation stratification was apparently well-controlled (lambda = 0.991). Population-specific Man-
hattan and QQ-plots are separately reported in S2 Fig. Based on the QQ-plot and lambda
value (0.969) for the USA2 cohort, the reconstructed control group for the MAGNet DCM
cases appears appropriate. For all loci, the effect of the lead SNP is quite homogeneous across
populations (Fig 2). Ten of the 11 SNVs encode missense residues, as expected from the
enrichment of the exome array for this category of variants.
ZBTB17-HSPB7 locus
The lead SNV, rs10927875 (ZBTB17, c.-3+222G>A, MAF = 0.31), is located in an intron of
ZBTB17. As observed in our earlier GWAS [3], this SNP confers a reduced risk of DCM
(OR = 0.77 (0.71–0.83), P = 8.1x10-13). Imputation revealed a large number of SNVs in strong
LD with rs10927875 (S3A Table), but as a result of the "Yin-Yang" haplotypic structure of the
region we could not determine the most likely causal variant or gene (Fig 3A). However, sev-
eral imputed SNVs located within or downstream the heat shock 27kDa protein family,
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member 7 gene (HSPB7) had slightly more significant P-values than rs10927875 (S3A Table).
Generally, SNVs within HSBP7 had more deleterious CADD scores than those within ZBTB17
or CLCNKA (another candidate within the region [4]). In addition, GTEx analysis showed that
HSPB7 is mostly expressed in the heart and skeletal muscles. Using GST pull-down experiment
and co-immunoprecipitation we also observed that recombinant BAG3 interacts with HSPB7
(Fig 4). Overall, this suggests that HSPB7 is the best candidate to explain the association of var-
iants in this region with DCM.
TTN locus
Titin is a major component of the sarcomere and an important familial DCM gene [12]. The
lead SNV, rs3829746 in (TTN, c.56704A>G, p.Ile18902Val, MAF = 0.23) confers a reduced
risk of DCM (OR = 0.81 (0.75–0.88), P = 3.4x10-7). A regional plot of all variants (genotyped
and imputed) shows that several are in tight LD with the lead SNV (Fig 3B) and associated
with DCM. Among these SNVs, rs2042996 (p.Thr21403Ile) has the highest CADD score (20.1)
(S3B Table). According to GTEx rs3829746 is associated with reduced TTN expression in the
left ventricle (P = 0.04) and atrial appendage (P = 0.006). Unlike TTN truncating variants that
cause DCM, the DCM-associated TTN missense variants present on the exome-array are inde-
pendent of TTN exon usage. (S1Methods—Exonusage in TTN).
Fig 1. Manhattan Plot of association P-values. 95,499 variants were investigated for association with DCM
by logistic regression analysis. Associations are summarized in a Manhattan plot (R/qqman package) which
displays the eleven SNVs significantly associated with DCM (Q-values < 0.01) as green dots. Note that the
applied logistic model assumed an additive mode of inheritance. For variants on chromosome 15 in the
ALPK3 region, a dominant mode of inheritance was better supported by the data (see Table 1 for
corresponding P-values)
doi:10.1371/journal.pone.0172995.g001
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SLC39A8 locus
Solute carrier family 39 member 8 gene encodes encodes a transmembrane metal-ion transporter
exhibiting highly pleiotropic effects. The lead SNV rs13107325 (SLC39A8, c.1171G>A, p.Ala391
Thr, MAF = 0.08) confers an increased risk of DCM (OR = 1.35 (1.20–1.52), P = 6.0x10-7). Impu-
tation reveals little genetic variability at this locus (Fig 3C, S3C Table) and rs13107325has the
highest CADD score (35.0), suggesting that it might be the causal variant. The possible implication
of this locus in DCM is intriguing, given that SLC39A8 is minimally expressed in the heart.
MLIP locus
Muscular Lamin A (LMNA)-interacting protein interacts with LMNA, a structural component
of nuclear lamina known to be implicated in familial DCM [13]. The lead SNV rs4712056
(MLIP, c.475G>A, p.Val159Ile, MAF = 0.35) is associated with an increased risk of DCM
(OR = 1.19 (1.11–1.28), P = 5.1x10-7). Several imputed variants in the gene are more strongly
associated with DCM than rs4712056 (Fig 3D, S3D Table). All of them are intronic or located
upstream of the sequence encoding the short cardiac transcript of MLIP. The strongest associa-
tion implicates rs35182047, a small intronic insertion (c.64-12401_64-12400insAT). Although
the CADD score of this variant is modest (2.33), its DCM-associated risk (OR = 1.30 (1.20–
1.40, P = 2.5x10-10) is substantially higher than that of rs4712056.
FLNC locus
Filamin C is an actin-crosslinking protein, specifically expressed in cardiac and skeletal mus-
cles. The lead SNV rs2291569 (FLNC, c.4700G>A, p.Arg1567Gln, MAF = 0.09) is associated
with a reduced risk of DCM (OR = 0.65 (0.57–0.74), P = 8.7x10-11). Fine mapping analysis
Table 1. Variants associated with DCM.
MAF OR (95% CI) P-value Q-value P-Het Gene AA Change
rs848210 A: 0.45 (0.39–0.49) 1.182 (1.11–1.26) 6.3x10-07 6.0x10-03 0.5 SPEN N/D
rs10927875 A: 0.31 (0.26–0.37) 0.768 (0.71–0.83) 8.1x10-13 3.9x10-08 0.83 ZBTB17 -
rs3829746 G: 0.23 (0.21–0.24) 0.810 (0.75–0.88) 3.4x10-07 4.6x10-03 0.039 TTN I/V
rs13107325 A: 0.08 (0.07–0.12) 1.348 (1.20–1.52) 6.0x10-07 6.0x10-03 0.61 SLC39A8 A/T
rs4712056 G: 0.35 (0.34–0.36) 1.191 (1.11–1.28) 5.1x10-07 6.0x10-03 0.53 MLIP V/I
rs2291569 A: 0.08 (0.05–0.09) 0.651 (0.57–0.74) 8.7x10-11 2.8x10-06 0.27 FLNC R/Q
rs2234962 G: 0.19 (0.15–0.22) 0.620 (0.57–0.68) 1.7x10-25 1.6x10-20 0.14 BAG3 C/R
rs3188055 G: 0.34 (0.33–0.35) 1.223 (1.14–1.31) 1.1x10-08 2.6x10-04 0.84 INPP5F N/D
rs1051168 A: 0.30 (0.27–0.35) 1.273 (1.16–1.40) 4.1x10-07 4.9x10-03 0.32 NMB P/T
rs3803403 G: 0.30 (0.28–0.35) 1.276 (1.16–1.40) 2.9x10-07 4.0x10-03 0.29 ALPK3 T/S
rs2303510 A: 0.31 (0.29–0.34) 0.824 (0.77–0.89) 1.5x10-07 2.3x10-03 0.023 FHOD3 V/I
For rs1051168 (NMB) and rs3803403 (ALPK3) the result of the dominant model is shown as it is better supported than the additive test which is presented
for all other variants. The minor frequency allele is the effect allele.
MAF: Minor allele frequencies (ranges across 6 populations).
OR: Odds-Ratio estimated using a logistic model adjusted on gender and first 20 PCs.
Q-value threshold (0.01)
Het: test of homogeneity of effects across populations.
SPEN: spen family transcriptional repressor; ZBTB17: zinc finger and BTB domain containing 17; TTN: titin; SLC39A8: solute carrier family 39 (zinc
transporter), member 8; MLIP: muscular LMNA-interacting protein; FLNC: filamin C, gamma; BAG3: BCL2-associated athanogene 3; INPP5F: inositol
polyphosphate-5-phosphatase F; NMB: neuromedin B; ALPK3: alpha-kinase 3; FHOD3: formin homology 2 domain containing 3.
doi:10.1371/journal.pone.0172995.t001
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Fig 2. Forest Plots of odd-ratios (log) in the different populations. The results show that the associations
were largely homogeneous across populations (See also heterogeneity column in Table 2)
doi:10.1371/journal.pone.0172995.g002
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shows that two imputed variants located in the 3’UTR of FLNC are in strong LD with rs22915
69 and exhibit similar ORs (Fig 3E, S3E Table).
BAG3 locus
This locus was the second one identified in our earlier GWAS.(3) rs2234962 (BAG3,c.451T>C, p.
Cys151Arg, MAF = 0.19) confers a reduced risk of DCM (OR = 0.62 (0.57–0.68), P = 1.7x10-25).
A nearby SNV, rs3188055, located in the INPP5F is no longer significant after conditioning on
rs2234962. When also considering imputed variants at the locus, rs2234962 is by far the most sig-
nificant and it also has the highest CADD score (24.2) (Fig 3F, S3F Table).
NMB-ALPK3 locus
Two missense variants in strong LD (r2 = 0.82), rs1051168 in Neuromedin B (NMB, c.217C>A,
p.Pro73Thr, MAF = 0.30) and rs3803403 in alpha-kinase 3 (ALPK3, c.1241C>G, p.Thr414Ser,
MAF = 0.30) are associated with DCM at this locus. The minor allele at both loci exerts a domi-
nant effect on DCM risk (OR = 1.27 [1.16–1.40]). Fine-mapping analysis identifies a single
major haplotypic structure encompassing NMB, ALPK3 and several other genes (Fig 3G).
CADD scores do not orient towards causal variants among these tightly associated SNVs (S3G
Table). However, GTEx indicates that the genes in the interval are not or very lowly expressed
in the heart or skeletal muscle, except ALPK3 which is almost exclusively expressed in these tis-
sues. ALPK3 encodes a nuclear kinase implicated in the differentiation of cardiomyocyte and
Alpk3-deficient mice develop cardiomyopathy [14].
Fig 3. Regional plots of association at 8 loci. P-values, obtained from logistic regression analysis of genotyped and
imputed variants in genomic regions demonstrating significant association with DCM are depicted. In each region, the
genotyped lead-SNV is identified by its position and the other variants are colored to reflect their LD with the lead-SNV.
doi:10.1371/journal.pone.0172995.g003
Fig 4. BAG3 interacts with HspB7. (A) GST Pull-Down showing interaction of GFP-BAG3 expressed in HEK293 cells and recombinant
GST-HSPB7. GFP-BAG3 was expressed in HEK293 cells (cell extract panel) and and GST-HSPB7 was produced in a bacterial expression system.
GST-HSPB7 co-sediment with GFP-BAG3 but not with GFP alone indicating specific BAG3/GST-HSPB7 interaction (Pull-Down panel). (B) Co-
immunoprecipitation experiment showing interaction of Flag-HSPB7 and GFP-BAG3 in HEK293 cells. GFP alone or GFP-BAG3 were co-expressed
together with Flag-HSPB7 in HEK293 cells (cell extract panel) and subjected to immunoprecipitation with an antibody against GFP. Only
GFP-BAG3 immunoprecipitated with FLAG-HSPB7 (IP:GFP panel). Western blottings in (A) and (B) used HSPB7 (for GST-HSPB7), GFP (for GFP
and GFP-BAG3), and α-tubulin specific antibodies.
doi:10.1371/journal.pone.0172995.g004
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FHOD3 locus
Formin homology 2 domain containing 3 regulates actin assembly and sarcomere organization
in striated muscles. The lead SNV rs2303510 (FHOD3, NM_025135.4:c.3591G>A,
NP_079411.2:p.Val1151>Ile, MAF = 0.31) is associated with a reduced risk of DCM
(OR = 0.82 (0.77–0.89), P = 1.5x10-07). Imputation identifies several SNVs, most of them intro-
nic, in strong LD with rs2303510 and clustered within a relatively narrow region of the FHOD3
sequence (Fig 3H, S3H Table). Among these SNVs, the highest CADD score (22.8) is observed
for the missense rs2303510 variant.
Tissue expression of identified candidate genes
According to GTEx, with the exception of SLC39A8, the best candidate genes at the DCM-
associated loci are all preferentially expressed in heart or skeletal muscle tissues. However,
except for TTN, their expression levels in these tissues are unaltered by the lead-SNVs.
Gene-level analysis
Because analysis of single SNVs lacks power for detecting association with rare variants, we
tested whether genotyped variants in the candidate regions were collectively associated with
DCM. A first analysis showed a significant association of rare variants (MAF<0.01) at the
ZBTB17 and TTN loci with DCM (Table 2). However, when conditioning on the lead SNP at
each locus, only the association of TTN rare variants remained significant (P = 0.013). When
including all variants (rare and common) in the analysis and conditioning on the lead SNVs,
there was still a significant association (P<0.05) at the ZBTB17, TTN and BAG3 loci which
implies residual associations independent of the lead-SNVs (Table 2).
Familial DCM gene-set analysis
Sixty genes are reported to be implicated in familial cardiomyopathies [2]. To investigate
whether these genes might also have a role in sporadic DCM, we tested their association at the
gene level. After discarding BAG3 and TTN and genes harboring no variant in our data set, 48
genes and 608 variants (478 of which are rare) were tested (S4 Table). No association was
observed for rare variants after Bonferroni correction for 48 genes. For common variants, the
only significant association was observed for MYBPC3 (4 variants, P = 5.7x10-5, P<0.003 after
Bonferroni correction). In the MYBPC3 gene, the most significant SNV had a P-value of
Table 2. Gene-level association analysis of genes identified in the SNP-level analysis
Region number of variant (rare
f<0.01)
All variants P-value
(adjusted$)
Rare variants P-value
(adjusted$)
Common variants P-value
(adjusted$)
ZBTB17 54 (47) 1.1x10-12 (0.007) 0.046 (0.4) 2.14x10-12 (0.0027)
TTN 457 (369) 3.1x10-06 (0.0083) 0.0085 (0.013) 1.20x10-05 (0.048)
SLC39A8 4 (2) 9.5x10-05 (0.23) 0.13 (0.12) 1.65x10-05 (0.5)
MLIP 24 (15) 1.2x10-04 (0.19) 0.91 (0.81) 1.68x10-06 (0.049)
FLNC 72 (61) 2.3x10-04 (0.46) 0.32 (0.4) 2.34x10-05 (0.48)
BAG3 32 (22) 2.6x10-20 (0.037) 0.23 (0.53) 4.36x10-23 (0.0094)
ALPK3 42 (33) 2.5x10-02 (0.8) 0.55 (0.53) 3.71x10-03 (0.89)
FHOD3 40 (30) 6.9x10-04 (0.27) 0.083 (0.086) 7.80x10-04 (0.77)
The gene-level analysis was performed using the R/SKAT_CommonRare function (See S1 Methods).
$ P-values adjusted on lead-SNV.
doi:10.1371/journal.pone.0172995.t002
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3.06x10-03. The entire set of 608 variants was associated with DCM (P = 0.0067) and the associ-
ation was strengthened for variants with a CADD severity score > 20 (n = 264, P = 0.0005);
both rare (P = 0.0033) and common variants (P = 0.019) contributed to this association
(Table 3).
Discussion
In this EWAS of sporadic DCM we confirmed associations with variants in ZBTB17-HSPB7
and BAG3 and identified six novel loci. Statistical analyses, cardiac tissue expression, and phys-
iology suggest that the most likely causal genes are HSPB7, BAG3, TTN, SLC39A8, MLIP,
FLNC, ALPK3 and FHOD3.
Our data provide evidence that non-coding variants close to or within HSPB7 are more
likely to account for the observed association at the ZBTB17 locus. The genetic mechanism
linking the risk haplotype to HSPB7 functional modulation in absence of detectable eQTL is
unknown. HSPB7 (commonly referred as cardiovascular Heat Shock Protein; cvHSP) is a mem-
ber of the small HSPB family of molecular chaperones. It is a potent polyglutamin aggregation
suppressor that assists the loading of misfolded proteins or small protein aggregates into autop-
hagosomes [15]. In addition, our in vitro experiments demonstrate a physical interaction of
BAG3 with HSPB7 (Fig 4) suggesting functional relationships between the 2 proteins that may
be relevant for their genetic implication in DCM pathophysiology. The strongest association
with sporadic DCM in our EWAS involved rs2234962which encodes a p.Cys151Arg substitu-
tion in BAG3. The interaction signal of BAG3 Arg151 and Cys151 isoforms with HSPB7 was
similar (data not shown), suggesting no direct effect of the polymorphism on HSPB7 binding
The p.Cys151Arg variant is located between two conserved Ile–Pro–Val (IPV) motifs involved
in BAG3 complex formation with HSPB6 and HSPB8. Interestingly, a p.Pro209Leu mutation
responsible for myofibrillar myopathy associated with cardiomyopathy is located in one of the
two IPV motifs [16]. Whether p.Cys151Arg modifies the interaction of BAG3 with HSPBs part-
ners and affects the functional potential of the complex is currently unknown.
Common haplotype-tagging variants of the titin gene were associated with small differences
in DCM risk in this EWAS. This extends the spectrum of TTN genetic variants that affect
DCM risk, from highly penetrant mutations responsible for familial DCM [12] to common
haplotypes with low penetrance associated with sporadic DCM. A potential consequence of
common DCM-associated TTN variants, in line with the pathogenic mechanisms suggested by
the candidate genes identified in this EWAS, is the proteotoxic effect of accumulating trun-
cated or aggregate prone mutant TTN in cardiomyocytes.
The rs13107325 SNV in SLC39A8 has been shown in GWAS to be associated with several
traits affecting cardiovascular risk, including blood pressure. It is therefore conceivable that it
has systemic consequences that raise the risk of DCM but were not considered in our disease
exclusion criteria. Because SLC39A8 encodes a zinc transporter [17], its association with DCM
may also be related to the cardioprotective role of zinc [18].
Table 3. DCM gene set association analysis
variants subset Number of variants (rare f<0.01) All variants P-value Rare variants P-value Common variants P-value
All 608 (478) 0.0067 0.013 0.091
CADD20 264 (228) 0.0005 0.0033 0.019
CADD25 71 (63) 0.016 0.047 0.064
CADD30 30 (26) 0.064 0.19 0.07
All variants on 48 familial DCM genes (excluding BAG3 and TTN) also categorized by CADD severity scores.
doi:10.1371/journal.pone.0172995.t003
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In the nuclear envelope, MLIP (also known as CIP) directly interacts with the N-terminal
region of lamin (LMNA) [19]. Dominant mutations in LMNA cause DCM and other heredi-
tary multisystemic diseases and several pathogenic mutations of LMNA are located in its
MLIP interacting domain [20]. In mice, Mlip interacts with Isl1, a transcription factor required
for cardiomyocyte differentiation, and represses its transcriptional activity [21]. Notably, the
DCM-associated SNV (rs4712056, p.Val159Ile) is located within the Isl1-interacting region of
MLIP. MLIP has recently been shown to be a key regulator of cardiomyopathy that has poten-
tial as a therapeutic target to attenuate heart failure progression [22].
Filamin C is involved in the organization of actin filaments, it serves as a scaffold for signal-
ing proteins and interacts with several Z-disk proteins. FLNC mutations in humans and mice
cause hypertrophic cardiomyopathy [23] and myofibrillar myopathy, a form of muscular dys-
trophy with concurrent cardiomyopathy [24]. These pathologies are characterized by myofi-
brillar disorganization, accumulation of myofibrillar degradation products and ectopic
expression of multiple proteins [25]. FLNC mutations induce massive protein aggregates
within skeletal muscle fibers and altered expression of chaperone proteins and components of
proteasomal and autophagic degradation pathways. Interestingly, functional interaction
between FLNC and HSPB7 or BAG3, two genes confirmed by this study, have been previously
reported [26,27]. In addition to the fact that BAG3 mutations also causes myofibrillar myopa-
thy it suggests the hypothesis that dysregulation of proteostasis could be a common mecha-
nism underlying myofibrillar myopathy and DCM.
Cardiac FHOD3 plays a crucial role in the sarcomere organization of cardiomyocytes, is
essential for heart myofibrillogenesis [28] and is required for the maintenance of the contrac-
tile structures in heart muscle. A cardiac isoform of FHOD3 is targeted to thin actin filaments
via phosphorylation of tyrosine residue preventing autophagy dependent degradation [29].
Most DCM-associated SNVs in our EWAS are clustered in a region in 3’ of FHOD3 that
encodes the Formin FH2 domain of the protein, which is implicated in actin polymerization
[30]. A FHOD3 variant, Y1249N, has been reported in a Japanese patient with a dominant
form of DCM. In vivo functional analysis showed that this variant may impair actin filament
assembly, thus providing some support for the implication of FHOD3 in the pathogenesis of
DCM [31].
Alpha-kinase 3 (ALPK3/MIDORI) was initially described as a myocyte-specific gene that
promotes differentiation of P19CL6 cells into cardiomyocytes [32]. The pattern of expression
of ALPK3 in differentiating cardiomyocytes nucleus is similar to that of transcription factors
specific of the cardiogenic lineage [33] but its function is still largely unknown. Recently reces-
sive mutations in ALPK3 have been reported to cause pediatric DCM [34].
In addition to TTN and BAG3, MYBPC3 was present in the cardiomyopathy gene-set [2]
and harbored variants associated with sporadic DCM in our EWAS. MYBPC3 is an actin,
myosin and titin interacting protein of the M-band of the sarcomere. Mutations in this gene
are a major cause of hypertrophic cardiomyopathy and have also been reported in familial
forms of DCM [35]. Coding variants in MYBPC3may affect actin-myosin interaction [36] and
concurrently interfere with the ubiquitin proteasome system and autophagy in humans and
animal models [37]. Both mechanisms could account for the association of common SNVs in
MYBPC3with sporadic DCM.
Considered as a whole, both rare and common variants with elevated CADD scores in the
cardiomyopathy gene-set were associated with sporadic DCM (S3 Table) indicating that other
loci than those found in this EWAS are involved in sporadic DCM, however identifying the
responsible genes will require larger studies.
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Proteostasis might be important for DCM
Three of the DCM-associated genes, FLNC, TTN (through its kinase activity) and cardiac spe-
cific FHOD3 encode maintenance partners of sarcomere and sarcomere-related structures,
including Z-disk or F-actin myofibrils [29,38,39], which are disorganized or degraded in
experimental models of cardiomyopathy [40]. Moreover the cellular level of FLNC, FHOD3
and TTN kinase targets such as MuRF2, appears regulated by proteostasis mechanisms
[26,29,39]. One of these mechanisms, BAG3-associated chaperone-assisted selective autophagy
(CASA) is described as a central adaptation mechanism that responds to acute physical exer-
cise and to repeated mechanical stimulation [41]. BAG3 inactivation also leads to Z-disk dis-
ruption in mice and fruit fly [26]. Based on the functional similarities (also pertaining to
HSPB7 and MYBPC3) characterizing several of the DCM-associated genes identified in this
study, we hypothesize that abnormal cardiomyocyte sarcomere maintenance and regulation of
autophagy is a potential mechanism involved in DCM pathophysiology is. Further experimen-
tal exploration of this hypothesis may yield novel therapeutic targets for DCM.
Limitations of this study
This study has some limitations. The recruitment was focused on a priori homogeneous sets of
patients and controls of European ancestry and outliers were excluded based on genomic data.
We also conducted a meta-analysis which did not reveal any significant heterogeneity across
populations. Despite these precautions, we cannot fully exclude undetected population stratifi-
cation. In addition, given the rather low prevalence of DCM, we conducted exome-wide geno-
typing in all available patients and controls instead of using a two-step discovery/replication
design. As a consequence, even if we provide a series of arguments supporting the identified
genes as plausible candidates, independent studies would certainly further refine and extend
our results. It is likely that a genome-wide tagging array not limited to exon regions would
identify other DCM-associated variants and loci than those reported here. Finally, as our
power analyses show, our EWAS had limited power to detect the collective effect of rare vari-
ants present in our data set at the gene level.
Conclusion
We identified 6 novel loci associated with sporadic DCM and confirmed two previously
reported associations with variants located within the ZBTB17-HSPB7 and BAG3 genes. Fine
mapping revealed that at the ZBTB17 locus HSPB7 is likely the implicated gene. The lead-
SNVs at all associated loci are common variants and conditioning on them reduced consider-
ably the associations of other variants in the regions of interest with DCM. We provide evi-
dence that 7 of the DCM-associated genes are very plausible candidates from a pathogenic
perspective.
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